Spectrum of drugs against atypical mycobacteria: How valid is the current practice of drug susceptibility testing and the choice of drugs?
- 31 December 1992
- journal article
- Published by Elsevier in Zentralblatt für Bakteriologie
- Vol. 277 (4), 474-484
- https://doi.org/10.1016/s0934-8840(11)80472-x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Diagnosis and Treatment of Disease Caused by Nontuberculous MycobacteriaAmerican Review of Respiratory Disease, 1990
- Permeability barrier to hydrophilic solutes in Mycobacterium cheloneiJournal of Bacteriology, 1990
- Bactericidal ActivityIn Vitroof Various Rifamycins againstMycobacterium aviumandMycobacterium tuberculosisAmerican Review of Respiratory Disease, 1990
- In vitro and in vivo activities of clarithromycin against Mycobacterium aviumAntimicrobial Agents and Chemotherapy, 1989
- MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugsAntimicrobial Agents and Chemotherapy, 1988
- Synergistic effects of antimycobacterial drag combinations onMycobacterium avium complex determined radiometrically in liquid mediumEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- In vitro activity of new rifamycins aganst rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteriaTubercle, 1987
- Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methodsAntimicrobial Agents and Chemotherapy, 1985
- LM 427,a new spiropiperidylrifamycin: In vitro and in vivo studies.The Journal of Antibiotics, 1983
- Basis for Lack of Drug Susceptibility of Atypical MycobacteriaClinical Infectious Diseases, 1981